论文部分内容阅读
目的:评价ST段抬高型急性心肌梗死(AMI)直接经皮冠状动脉介入(PCI)治疗时应用远端保护装置(DPD)ANGIOGUARD XP的安全性和疗效。方法:按照直按PCI时是否应用ANGIOGUARD XP DPD,将24例AMI患者分成DPD组(12例)和对照组(12例)。比较两组各项临床资料。结果:与对照组比较,DPD组未明显延长X线暴光时间和手术时间(16.5±4.8%vs 17.4±7.8%,35.8±10.5%vs 42.5±5.5%;P>0.05)。DPD均成功地一次通过病变且全部成功完成手术。术后DPD组ST段回落率和左室射血分数均显著高于对照组100%vs 67%,65.2±7.6%vs 51.5±5.5%:P<0.05]。结论:在AMI直接PCI治疗中,对于有选择的病变,应用ANGIOGUARD XP DPD安全可行且可显著改善心肌组织再灌注和心功能,值得推广应用。
Objective: To evaluate the safety and efficacy of ANGIOGUARD XP with DPD in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing direct percutaneous coronary intervention (PCI). METHODS: Twenty-four AMI patients were divided into DPD group (n = 12) and control group (n = 12) according to whether ANGIOGUARD XP DPD was used during direct PCI. Compare two sets of clinical data. Results: Compared with the control group, the DPD group did not significantly prolong the X-ray exposure time and operation time (16.5 ± 4.8% vs 17.4 ± 7.8%, 35.8 ± 10.5% vs 42.5 ± 5.5%; P> 0.05). DPD successfully passed the lesion all at once and successfully completed the operation. The postoperative STD drop and left ventricular ejection fraction in DPD group were significantly higher than those in control group (100% vs 67%, 65.2 ± 7.6% vs 51.5 ± 5.5%, P <0.05, respectively). CONCLUSIONS: ANGIOGUARD XP DPD is safe and feasible for selective lesions in AMI-treated PCI and can significantly improve myocardial tissue reperfusion and cardiac function, which is worthy of promotion and application.